Olaparib With Ceralasertib in Recurrent Osteosarcoma

Part of paid clinical trials in San Francisco, California.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT04417062
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Osteosarcoma
  • Osteosarcoma Recurrent

Eligibility Criteria

Sex
ALL
Age
12 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
  • Ceralasertib — DRUG
    Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.

Study Details

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib

Key Dates

Start date
Nov 24, 2020
Status verified
Feb 2026
Primary completion
Jun 1, 2025
Completion
Jun 1, 2026

Study Design

Enrollment
63 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Olaparib-Ceralasertib
    Unresectable disease (can not be surgically removed) will be enrolled into Cohort 1 and Resectable disease (can be surgically removed) which is limited only to the lung parenchyma will be enrolled into Cohort 2. * Olaparib at a predetermined dose orally 2 times a day on days 1-28 * Ceralasertib will be given at a predetermined dose orally 2 times a day on days 1-14 in 28-day study cycles. Patients can remain on treatment for up to 2 years if disease progression has not occurred.

Primary Outcome Measure

Cohort 1 Event Free at 4 months [ Time Frame: 4 months after start of protocol therapy ]

Locations (4)

FacilityCityStateZIPSite coordinators
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology OncologySan FranciscoCalifornia94158-
Dana Farber Cancer InstititeBostonMassachusetts02115-
Memorial Sloan KetteringNew YorkNew York10065-
MD AndersonHoustonTexas77030-

Find similar trials in San Francisco, CA

By research site
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology· San Francisco, CADana Farber Cancer Institite· Boston, MAMemorial Sloan Kettering· New York, NYMD Anderson· Houston, TX

Related Studies